- Home
- EWTX vs RPD Comparison
EWTX vs RPD Comparison
Compare EWTX & RPD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EWTX
- RPD
- Stock Information
- Founded
- EWTX 2017
- RPD 2000
- Country
- EWTX United States
- RPD United States
- Employees
- EWTX N/A
- RPD N/A
- Industry
- EWTX Biotechnology: Pharmaceutical Preparations
- RPD Computer Software: Prepackaged Software
- Sector
- EWTX Health Care
- RPD Technology
- Exchange
- EWTX Nasdaq
- RPD Nasdaq
- Market Cap
- EWTX 1.5B
- RPD 1.5B
- IPO Year
- EWTX 2021
- RPD 2015
- Fundamental
- Price
- EWTX $14.63
- RPD $22.53
- Analyst Decision
- EWTX Buy
- RPD Hold
- Analyst Count
- EWTX 9
- RPD 20
- Target Price
- EWTX $39.89
- RPD $32.61
- AVG Volume (30 Days)
- EWTX 723.3K
- RPD 742.7K
- Earning Date
- EWTX 08-07-2025
- RPD 08-07-2025
- Dividend Yield
- EWTX N/A
- RPD N/A
- EPS Growth
- EWTX N/A
- RPD N/A
- EPS
- EWTX N/A
- RPD 0.41
- Revenue
- EWTX N/A
- RPD $849,159,000.00
- Revenue This Year
- EWTX N/A
- RPD $2.78
- Revenue Next Year
- EWTX N/A
- RPD $3.91
- P/E Ratio
- EWTX N/A
- RPD $55.07
- Revenue Growth
- EWTX N/A
- RPD 6.19
- 52 Week Low
- EWTX $10.60
- RPD $21.61
- 52 Week High
- EWTX $38.12
- RPD $44.48
- Technical
- Relative Strength Index (RSI)
- EWTX 58.59
- RPD 42.90
- Support Level
- EWTX $13.34
- RPD $22.16
- Resistance Level
- EWTX $14.08
- RPD $23.26
- Average True Range (ATR)
- EWTX 0.57
- RPD 0.78
- MACD
- EWTX 0.16
- RPD -0.08
- Stochastic Oscillator
- EWTX 98.60
- RPD 10.03
About EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.
About RPD Rapid7 Inc.
Founded in 2000, Rapid7 is a cybersecurity company that began providing vulnerability management solutions. It has, however, expanded its portfolio to provide extended detection and response; security information and event management; cloud security, threat intelligence, and application security; and security orchestration, automation, and response. The Boston-based company went public in 2015.